Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 3/20 | 0.45 |
| ▸ | CNR1 | P21554 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.43 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11878066 | 0.98 | SMN1; SMN2 (0.58) | SMN1; SMN2L3MBTL1ACKR3ALDH1A1GAA | |
| SCHEMBL2962867 | 0.92 | SMYD3 (0.49) | SMN1; SMN2L3MBTL1ACKR3ALDH1A1GAA | |
| SCHEMBL19710364 | 0.84 | SMYD3 (0.61) | SMN1; SMN2L3MBTL1 | |
| SCHEMBL21489887 | 0.84 | SMYD3 (0.61) | SMN1; SMN2L3MBTL1 | |
| SCHEMBL4435015 | 0.81 | SMN1; SMN2 (0.43) | SMN1; SMN2L3MBTL1ACKR3HTTMEN1 | |
| SCHEMBL19710371 | 0.79 | SMYD3 (0.60) | — | |
| SCHEMBL28132511 | 0.76 | ALDH1A1 (0.47) | SMN1; SMN2L3MBTL1ALDH1A1GAAHTT | |
| SCHEMBL2425813 | 0.75 | JAK3 (0.47) | SMN1; SMN2ACKR3ALDH1A1RAB9ANPC1 | |
| SCHEMBL9651228 | 0.74 | SIGMAR1 (0.61) | L3MBTL1ACKR3CYP1A2CYP2C19CYP3A4 | |
| SCHEMBL28133337 | 0.74 | ALDH1A1 (0.45) | SMN1; SMN2L3MBTL1ALDH1A1GAAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7763607-B2 | Pharmaceutical compositions comprising CBx cannabinoid receptor modulators and potassium channel modulators | SOLVAY PHARMACEUTICALS GMBH (DE) | 2010-07-27 | — | — | US | disclosed |
| CN-101431998-A | Containing CBxPharmaceutical compositions of cannabinoid receptor modulators and potassium channel modulators | SOLVAY PHARM GMBH (DE) | 2009-05-13 | — | — | CN | disclosed |
| US-20070254862-A1 | Pharmaceutical compositions comprising CBx cannabinoid receptor modulators and potassium channel modulators | SOLVAY PHARMACEUTICALS GMBH (DE) | 2007-11-01 | — | — | US | disclosed |
| US-4542139-A | HYPOGLYCEMIC AGENTS | HOECHST AKTIENGESELLSCHAFT (DE) | 1985-09-17 | — | — | US | disclosed |
| US-4379785-A | Heterocyclic substituted sulfonyl ureas, and their use | HOECHST AKTIENGESELLSCHAFT (DE) | 1983-04-12 | — | — | US | disclosed |
| US-4379153-A | Benzenesulfonyl ureas, and pharmaceutical preparations | HOECHST AKTIENGESELLSCHAFT (DE) | 1983-04-05 | — | — | US | disclosed |
| US-4325963-A | ANTIDIABETIC AGENT | HOECHST AKTIENGESELLSCHAFT (DE) | 1982-04-20 | — | — | US | disclosed |
| US-4315940-A | Antidiabetic 1-piperidine-sulfonylureas | HOECHST AKTIENGESELLSCHAFT (DE) | 1982-02-16 | — | — | US | disclosed |
| US-4282239-A | HYPOTENSIVE AGENTS | HOECHST AKTIENGESELLSCHAFT (DE) | 1981-08-04 | — | — | US | disclosed |
| US-4157395-A | TREATMENT OF DIABETES | HOECHST AKTIENGESELLSCHAFT (DE) | 1979-06-05 | — | — | US | disclosed |
| US-4132795-A | Benzenesulfonyl ureas and their use for the treatment of diabetes mellitus | HOECHST AKTIENGESELLSCHAFT (DE) | 1979-01-02 | — | — | US | disclosed |
| US-4025519-A | HYPOGLYCEMIC AGENTS | HOECHST AKTIENGESELLSCHAFT (DT) | 1977-05-24 | — | — | US | disclosed |
| US-3962244-A | LOWERING OF BLOOD-SUGAR LEVELS | HOECHST AKTIENGESELLSCHAFT (DT) | 1976-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254862-A1 | Pharmaceutical compositions comprising CBx cannabinoid receptor modulators and potassium channel modulators | CNR1, CNR2, KCNJ11 | SMN1; SMN2 2885/4885L3MBTL1 4854/4885ACKR3 2123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.